Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
01 1Tofigh Daru
02 1LGM Pharma
03 1Dr. Reddy's Laboratories
04 1HRV Global Life Sciences
05 1Omgene Life Sciences Pvt. Ltd
06 1Alembic Pharmaceuticals Limited
07 1Auro Peptides Limited
08 1Aurobindo Pharma Limited
09 1Biocon
10 1Cipla
11 1CordenPharma
12 1GLAND PHARMA LIMITED
13 1Hybio Pharmaceutical
14 1KinBio
15 1Natco Pharma
16 1Piramal Pharma Solutions
17 1Sajjala Bio Labs
18 1TAPI Technology & API Services
19 1Tecoland Corporation
01 1China
02 1Germany
03 11India
04 1Iran
05 2Israel
06 3U.S.A
01 4Active
02 1Inactive
03 14Blank
01 19Blank
01 19Blank
01 1WC-0014
02 1WC-0038n
03 1WC-0067
04 1WC-0427A3-4
05 15Blank
Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-945
Start Marketing Date : 2012-03-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-02-08
Pay. Date : 2020-12-24
DMF Number : 35493
Submission : 2020-12-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33092
Submission : 2018-09-12
Status : Active
Type : II
Date of Issue : 2022-08-04
Valid Till : 2025-03-04
Written Confirmation Number : WC-0427A3-4
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-07
Pay. Date : 2018-02-09
DMF Number : 28989
Submission : 2014-12-25
Status : Active
Type : II
NDC Package Code : 14403-0008
Start Marketing Date : 2016-08-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Date of Issue : 2019-06-26
Valid Till : 2022-06-25
Written Confirmation Number : WC-0014
Address of the Firm :
We have 19 companies offering Glatiramer Acetate
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?